Pathophysiology of Liver Diseases

Pathophysiology of colored DiseasesONG SUAN cuskLiver FailureThe colored is responsible for regulatory, detoxification, metabolic and synthetic activities. Liver cell known as hepatocyte, is responsible for about 500 or more specific biologic processes 2.Liver harm occurs when large split of the liver become damaged and the liver is dys act upon 1. Liver also-ran occurs over many years and gradually. However, the acute liver failure is elusive to detect initially and occurs rapidly (as rapid as 48 hours) 1. continuing liver failure is caused by excessive alcohol intake, Hepatitis B or C, malnutrition, Hemochromatosis (body absorb and store too much iron) and cirrhosis of the liver (irreversible instigative sickness) 2.Figure 1 show the stages of liver damage which eventually travel by to cirrhosis.Liver HepatitisHepatitis means inflammation of the liver. Hepatitis B and hepatitis C is the most roughhewn hepatitis which can blend in to the liver damage caused by their chro nic forms. viral hepatitis is cleared from the body in a period ranging from weeks to months, by the repellent system but when it is not as seen in chronic hepatitis, the disease must be managed medically 5.Hepatitis can in like manner be brought on by excess alcohol consumption or inherited (congenital hepatitis)5. When hepatitis leftfield untreated, it can damage the liver over many years, eventually resulting in cirrhosis 5.Liver CirrhosisCirrhosis is a condition in which normal, healthy hepatocyte are damaged and replaced by nodular and fibrotic tissue. A cirrhosis-damaged liver can cause decreased hepatic function and widespread opening of many body functions 3.For cirrhosis, the biliary channels become obstructed and caused adit hypertension. The hypoxic necrosis is developed as a result of contrast circulation is shunted international from the liver (due to neovascularisation) 4Figure 2 shows the normal appearance of the cells of the liver, compared to cells of cirrh otic livers.Hepato pulmonic syndrome (HPS)Hepatopulmonary syndrome is the clinical kindred between hepatic dysfunction and the existence of pulmonary vascular dilatation which can result in a range of arterial oxygenation abnormalities 6.HPS is delimit by the presence of chronic liver disease abnormal arterial oxygenation or an arterial partial stuff of oxygen in the absence seizure of an alternate cause and evidence of intrapulmonary vascular dilatations (IPVDs) 7PathophysiologyHepatopulmonary syndrome occurs mostly in patients who have established cirrhosis and entrance hypertension 8. From a pathophysiological rouse of view, abnormal intrapulmonary vascular dilatation is linked to portal hypertension, which in itself leads to altered bowel perfusion and an increase rate of enteral translocation of gram-negative bacterium and endotoxin.This process in turn stimulates the release of vasoactive mediators, which include tumour necrosis factor, haem-oxygenase-derived carbon mono xide, and nitric oxide. The increased production of nitric oxide in the lung plays a central part in the pathogenesis of the hepatopulmonary syndrome 8.Increased concentrations of exhaled nitric oxide are positively correlated with the increase of alveoloarterial oxygen difference. The constitutive and the inducible isoforms of nitricoxide synthase have been implicated in this process.In addition, the endothelin system, especially abnormal activation and increased expression of endothelial type B endothelin receptors, is implicated in the pathogenesis of the hepatopulmonary syndrome 8. In patients who have pulmonary hypertension, endothelin predominantly exerts vasoconstrictive and mitogenic effects due to activation of type A and type B endothelin receptors on pulmonary arterial smooth heft cells 8. (Refer to work 3)Figure 3 show in presence of portal hypertension, hepatic production occurs of endothelin-1 and expression of endothelial type B receptors, but no type A receptors in crease in pulmonary vasculature. signalise via endothelially expressed endothelin B receptor leads to increase NO production by eNOS, with the overall effect of pulmonary vascular dilatation.Below is how defective deduction and metabolism of pulmonary vasoactive substance lead to intrapulmonary Vasodilation.Due to the vasodilation and reading of shunt, the blood move is not uniform leading to ventilatation-pefusion mismatch and also restricts the oxygen molecules to reach the centre of the capillaries and hemoglobin in the erythrocyte 9. (Refer to figure 4)Figure 4 Ventilation-perfusion mismatches the oxygen reach the capillaries and blood.The nonuniform perfusion blood flow may lead to the formation of functional intrapulmonary vascular dilations which is the major(ip) cause of hypoxemia and the defining feature of HPS 9.The hyperdynamic circulation as well as the increased cardiac output which associated with liver disease lops the transit time of blood in the lung vasculatur e, thus the time available for the oxygen diffusion is reduced. This in turn contributes to the hypoxemia 9.HPS also caused a decreased arterial partial pressure of oxygen (PO2) as a result of the inability of oxygen molecules to circulate to the center of the dilated pulmonary capillaries to oxygenate the haemoglobin in the erythrocytes 8.Figure 5 shows illustration of precapillary pulmonary vascular dilatations.On the separate(a) hand, the increasing of dental consonant PO2 with supplement oxygen may increase the blood arterial PO2 and mitigate the hypoxemia 8.HPS patients have been reported to have decreased pulmonary vascular foe and decreased hypoxic pulmonary vascular constriction 8.Hepatorenal syndrome (HRS)Hepatorenal syndrome (HRS) is generally occurs in patients with cirrhosis and portal hypertension 10. HRS is characterised by major disturbances in circulatory function and renal failure 10. Intense vasoconstriction of the renal circulation has resulted in renal failu re 10.The HRS is the final consequence of extreme point underfilling of the arterial circulation secondary to arterial vasodilatation in the intuitive vascular bed 10, 11. The principle abnormality in the systemic circulation is low arterial pressure caused by greatly reduced chalk up systemic vascular resistance 11. The prognosis remains poor, particularly when in that location is rapidly progressive renal failure 11.HRS occurs in the setting of cirrhosis predominantly, but it can also be developed in other types of chronic liver disease like alcoholic hepatitis.Figure 6 Proposed pathogenesis of HRS in cirrhosis, according to the arterial vasodilatation 13The mechanism of HRS is vasoconstriction of the renal circulation is multifactorial, involving disturbance in the activity and circulatory function of systemic and renal vasoactive mechanisms 13.There is blunt arterial underfilling in the systemic circulation which is related to the portal hypertension 13. The arterial underfi lling is caused by the vasodilatation of the splanchnic circulation related to increased splanchnic production of vasodilator substances, particularly nitric oxide 17.The increased activity of the pressor systems caused greatly reduce in renal perfusion and GFR however tubular function is preserved 13,14,16.The vasoconstrictor system has resulted in the safekeeping in free water (arginine vasopressin) and retention in sodium (renin-angiotensin and sympathetic nervous system) that occurs in advanced cirrhosis 15, 16.In the early phases of decompensated cirrhosis, increased synthesis of renal vasodilator factors (mainly prostaglandins) caused criminal maintenance of renal perfusion within the normal range because of 17.In later phases of the disorder, renal perfusion cannot be maintained because maximum activation of vasoconstrictor systems caused by the extreme arterial underfilling, has decreased production of renal vasodilator factors, or both, and lead to HRS developement 17.Th e activation of vasoconstrictor systems also results in vasoconstriction of some vascular beds other than the kidneys, including the legs, arms and brain. Due to the greatly increased local production of vasodilators, the splanchnic area escapes the effect of vasconstrictors 18.ReferencesWebmd.com. (2014).Liver failure causes, symptoms, treatments, tests more. online Retrieved from http//www.webmd.com/digestive-disorders/digestive-diseases-liver-failure Accessed 11 Jan 2014.Vitaltherapies.com. (2014).Liver disease vital therapies. online Retrieved from http//vitaltherapies.com/liver-disease/ Accessed 11 Jan 2014.Hn632campus.wikispaces.com. 2014.HN632campus Cirrhosis. online Available at https//hn632campus.wikispaces.com/Cirrhosis Accessed 11 Jan 2014.Buob, S., Johnston, A. N., Webster, C. R. L. (2011). Portal hypertension pathophysiology, diagnosis, and treatment. daybook of veteran Internal Medicine,25(2), 169-186.Livermd.org. (2014).Hepatitis cirrhosis. online Retrieved from http//livermd.org/hepatitis.html Accessed 11 Jan 2014.Krowka, M. J., Cortese, D. A. (1994). Hepatopulmonary syndrome. Current concepts in diagnostic and therapeutic considerations.CHEST Journal,105(5), 1528-1537.Fritz, J. S., Fallon, M. B., Kawut, S. M. (2013). pulmonic Vascular Complications of Liver Disease.American journal of respiratory and critical care medicine,187(2), 133-143Hoeper, M. M., Krowka, M. J., Strassburg, C. P. (2004). Portopulmonary hypertension and hepatopulmonary syndrome.The Lancet,363(9419), 1461-1468Zhang, J., Fallon, M. B. (2012). Hepatopulmonary syndrome update on pathogenesis and clinical features.Nature Reviews Gastroenterology and Hepatology,9(9), 539-549.Ncbi.nlm.nih.gov. (2014).Hepatorenal syndrome national library of medicine pubmed health. online Retrieved from http//www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001519/ Accessed 12 Jan 2014.Emedicine.medscape.com. (2014).Medscape medscape access. online Retrieved from http//emedicine.medscape.com/ar ticle/178208-overviewa0104 Accessed 11 Jan 2014.Gins, P., Guevara, M., Arroyo, V., Rods, J. (2003). Hepatorenal syndrome.The Lancet,362(9398), 1819-1827.Arroyo, V., Gins, P., Gerbes, A. L., Dudley, F. J., Gentilini, P., Laffi, G., Schlmerich, J. (1996). Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.Hepatology,23(1), 164-176.Arroyo, V., Guevara, M., Gins, P. (2002). Hepatorenal syndrome in cirrhosis pathogenesis and treatment.Gastroenterology,122(6), 1658-1676.Schrier, R. W., Arroyo, V., Bernardi, M., Epstein, M., Henriksen, J. H., Rods, J. (1988). marginal arterial vasodilation hypothesis a proposal for the initiation of renal sodium and water retention in cirrhosis.Hepatology,8(5), 1151-1157.Schrier, R. W., Niederberger, M., Weigert, A., Gins, P. (1994). Peripheral arterial vasodilatation determining factor of functional spectrum of cirrhosis. InSeminars in liver disease(Vol. 14, No. 1, pp. 14-22).Martin, P. Y., Gins, P., Sc hrier, R. W. (1998). Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.New England Journal of Medicine,339(8), 533-541.Angeli, P., Merkel, C. (2008). Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis.Journal of hepatology,48, S93-S103.